Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV

Downloaded from https://aidsinfo.nih.gov/guidelines on 8/26/2020

Visit the AIDSinfo website to access the most up-to-date guideline.

Register for e-mail notification of guideline updates at https://aidsinfo.nih.gov/e-news.
The older NNRTI DLV is no longer commonly used in clinical practice and is not listed in this table. Please refer to the FDA product label for DLV for information regarding this drug.

<table>
<thead>
<tr>
<th>Generic Name (Abbreviations)</th>
<th>Trade Name</th>
<th>Formulations</th>
<th>Dosing Recommendations&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Elimination/Metabolic Pathway</th>
<th>Serum Half-Life</th>
<th>Adverse Events&lt;sup&gt;b&lt;/sup&gt;</th>
</tr>
</thead>
</table>
| **Doravirine (DOR)** | **Pifeltro** | Pifeltro: • 100 mg tablet Also available as part of the STR Delstrigo (DOR/TDF/3TC)<sup>c</sup> | Pifeltro: • One tablet once daily See Appendix B, Table 1 for dosing information for Delstrigo. | CYP3A4/5 substrate | 15 hours | Nausea
Dizziness
Abnormal dreams |
| **Efavirenz (EFV)** | **Sustiva** | **Note:** Generic product is available. | **Generic:** • 600 mg tablet **STRs that Contain EFV:** • Atripla (EFV/TDF/FTC) • Symfi (EFV 600 mg/TDF/3TC) • Symfi Lo (EFV 400 mg/TDF/3TC) | Metabolized by CYP2B6 (primary), 3A4, and 2A6 CYP3A4 mixed inducer/inhibitor (more an inducer than an inhibitor) CYP2B6 and 2C19 inducer | 40–55 hours | Rash<sup>d</sup>
Neuropsychiatric symptoms<sup>e</sup>
Serum transaminase elevations
Hyperlipidemia
Use of EFV may lead to false-positive results with some cannabinoid and benzodiazepine screening assays.
QT interval prolongation |
| **Etravirine (ETR)** | **Intence** | **Intence:** • 25, 100, and 200 mg tablets | **Intence:** • ETR 200 mg twice daily Take following a meal. | CYP3A4, 2C9, and 2C19 substrate CYP3A4 inducer CYP2C9 and 2C19 inhibitor | 41 hours | Rash, including Stevens-Johnson syndrome<sup>e</sup>
HSRs, characterized by rash, constitutional findings, and sometimes organ dysfunction (including hepatic failure), have been reported.
Nausea |
### Appendix B, Table 4. Characteristics of Non-Nucleoside Reverse Transcriptase Inhibitors  *(Last updated December 18, 2019; last reviewed December 18, 2019)*

<table>
<thead>
<tr>
<th>Generic Name (Abbreviations)</th>
<th>Trade Name</th>
<th>Formulations</th>
<th>Dosing Recommendations</th>
<th>Elimination/Metabolic Pathway</th>
<th>Serum Half-Life</th>
<th>Adverse Events</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Nevirapine (NVP)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Viramune or Viramune XR</td>
<td></td>
<td>Viramune:  • 200 mg tablet  • 50 mg/5 mL oral suspension Viramune XR:  • 400 mg tablet Generic:  • 200 mg tablet  • 400 mg extended release tablet  • 50 mg/5 mL oral suspension</td>
<td>Viramune:  • NVP 200 mg once daily for 14 days (lead-in period); thereafter, NVP 200 mg twice daily, or  • NVP 400 mg (Viramune XR tablet) once daily Take without regard to meals. Repeat lead-in period if therapy is discontinued for &gt;7 days. In patients who develop mild-to-moderate rash without constitutional symptoms, continue lead-in dose until rash resolves, but do not extend lead-in period beyond 28 days total.</td>
<td>CYP450 substrate CYP3A4 and 2B6 inducer Contraindicated in patients with moderate to severe hepatic impairment. Dose adjustment is recommended in patients on hemodialysis (see Appendix B, Table 10).</td>
<td>25–30 hours</td>
<td>Rash, including Stevens-Johnson syndrome&lt;sup&gt;d&lt;/sup&gt; Symptomatic Hepatitis:  • Symptomatic hepatitis, including fatal hepatic necrosis, has been reported.  • Rash has been reported in approximately 50% of cases.  • Symptomatic hepatitis occurs at a significantly higher frequency in ARV-naive female patients with pre-NVP CD4 counts &gt;250 cells/mm&lt;sup&gt;3&lt;/sup&gt; and in ARV-naive male patients with pre-NVP CD4 counts &gt;400 cells/mm&lt;sup&gt;3&lt;/sup&gt;.  • NVP should not be initiated in these patients unless the benefit clearly outweighs the risk.</td>
</tr>
<tr>
<td>Note: Generic products are available.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Rilpivirine (RPV)</strong></td>
<td></td>
<td>Edurant:  • 25 mg tablet STRs that Contain RPV:&lt;sup&gt;c&lt;/sup&gt;  • Complera (RPV/TDF/FTC)  • Juluca (DTG/RPV)  • Odefsey (RPV/TAF/FTC)</td>
<td>Edurant:  • RPV 25 mg once daily Take with a meal. See Appendix B, Table 1 for dosing information for STRs that contain RPV.</td>
<td>CYP3A4 substrate</td>
<td>50 hours</td>
<td>Rash&lt;sup&gt;d&lt;/sup&gt; Depression, insomnia, headache Hepatotoxicity QT interval prolongation</td>
</tr>
<tr>
<td><em>Edurant</em></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup> For dose adjustments in patients with renal or hepatic insufficiency, see Appendix B, Table 10. When no food restriction is listed, the ARV drug can be taken with or without food.

<sup>b</sup> Also see Table 17.

<sup>c</sup> See Appendix B, Table 1 for information about these formulations.

<sup>d</sup> Rare cases of Stevens-Johnson syndrome have been reported with the use of most NNRTIs; the highest incidence of rash was seen among patients who were receiving NVP.

<sup>e</sup> Adverse events can include dizziness, somnolence, insomnia, abnormal dreams, depression, suicidality (e.g., suicide, suicide attempt or ideation), confusion, abnormal thinking, impaired concentration, amnesia, agitation, depersonalization, hallucinations, and euphoria. Approximately 50% of patients who are receiving EFV may experience any of these symptoms. Symptoms usually subside spontaneously after 2–4 weeks, but discontinuation of EFV may be necessary in a small percentage of patients. Late-onset neurotoxicities, including ataxia and encephalopathy, have been reported.

**Key:** 3TC = lamivudine; ARV = antiretroviral; CD4 = CD4 T lymphocyte; CYP = cytochrome P; DLV = delavirdine; DOR = doravirine; DTG = dolutegravir; EFV = efavirenz; ETR = etravirine; FDC = fixed-dose combination; FTC = emtricitabine; HSR = hypersensitivity reaction; NNRTI = non-nucleoside reverse transcriptase inhibitor; NVP = nevirapine; RPV = rilpivirine; STR = single-tablet regimen; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate; XR = extended release